Erase Imperfection MDA-A-128-05

Merck KGaA
Phase
Product
INCI Name
Supplier
Volume
A
RonaCare® AP
BIS-ETHYLHEXYL HYDROXYDIMETHOXY BENZYLMALONATE
1
2.00
Xiameter® PMX-0345
CYCLOPENTASILOXANE, CYCLOHEXASILOXANE
2
5.00
Crodamol DA
DIISOPROPYL ADIPATE
3
7.00
Paraffin liquid
PARAFFINUM LIQUIDUM (MINERAL OIL)
1
2.00
B
Sepiplus 400
POLYSORBATE 20, POLYACRYLATE 13, POLYISOBUTENE
4
2.00
C
RonaCare® Salicylic Acid
Salicylic Acid
1
1.00
Timiron® Silk Green
CI 77891 (TITANIUM DIOXIDE), MICA, TIN OXIDE
1
3.00
RonaCare® Ectoin
ECTOIN
1
0.50
Glycerol 85%
GLYCERIN, AQUA (WATER)
1
3.00
Titriplex® III
DISODIUM EDTA
1
0.10
Preservatives
qs
Water, demineralized
ad 100

Preparation:

Dissolve ingredients of phase A until homogenus. Add B under stirring in the premixed phase C.Add A to B/C while stirring. Homogenize.Finally add phase D.

Notes:

Appearence: white gel with green shimmerpH (23°C): 3.5Viscosity: 20000 mPa.s (Brookfield RV II+, spindle C, 10rpm) at 23°CStability: 3 month at 40°C, FTC(-5°C to 40°C), 5°C, RT and 1 week at 50°C (1) Merck KGaA, Darmstadt, Germany / EMD Chemicals (2) Dow Corning (3) Croda GmbH (4) Seppic GmbH (5) Schülke & Mayr GmbH
Disclaimer

While every effort has been made to reproduce these formulations correctly, the Publisher of this website cannot accept any liability for the information presented. All formulations are provided in good faith, but no warranty is given as to accuracy of information or results, or suitability for a particular use, nor is freedom from patent infringement to be inferred. Formulations are offered solely for consideration by the participating manufacturers. Continued use of this web site infers acceptance of this disclaimer.

Latest Issues

IFSCC 2024

Recanto das Cataratas Thermas Resort, Iguazu Falls, Brazil
14th - 17th October 2024

SEPAWA

Estrel Congress Center, Berlin
16th - 18th October 2024